Conference
Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial
Abstract
Abstract
Background: High dose chemotherapy followed by autologous stem cell transplant (ASCT) is the standard curative option for patients with relapsed or refractory, chemosensitive, aggressive non-Hodgkin lymphoma (NHL). The optimal timing for ASCT following salvage chemotherapy is not known. Cancer Care Ontario (CCO)-the cancer agency for Ontario, Canada's largest province-treatment guidelines recommend that no more than …
Authors
Skamene T; Jiang W; Meyer RM; Crump M; Kuruvilla J; Kouroukis CT; Luminari S; Couban S; Cheung MC; Rizzieri DA
Volume
128
Publisher
American Society of Hematology
Publication Date
December 2, 2016
DOI
10.1182/blood.v128.22.690.690
Conference proceedings
Blood
Issue
22
ISSN
0006-4971